BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hsu WF, Lai HC, Su WP, Lin CH, Chuang PH, Chen SH, Chen HY, Wang HW, Huang GT, Peng CY. Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents. BMC Gastroenterol 2019;19:63. [PMID: 31029101 DOI: 10.1186/s12876-019-0973-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Huynh T, Ma S, Hu KQ. HCV direct acting antiviral treatment leads to highly durable rates of ALT and AST lower than 30/19 criteria and improved APRI and FIB-4 scores. Hepatol Commun 2022. [PMID: 36221305 DOI: 10.1002/hep4.2098] [Reference Citation Analysis]
2 Rau M, Buggisch P, Mauss S, Boeker KHW, Klinker H, Müller T, Stoehr A, Schattenberg JM, Geier A. Prognostic impact of steatosis in the clinical course of chronic HCV infection—Results from the German Hepatitis C-Registry. PLoS ONE 2022;17:e0264741. [DOI: 10.1371/journal.pone.0264741] [Reference Citation Analysis]
3 Li XH, Huang R, Yang M, Wang J, Gao YH, Jin Q, Ma DL, Wei L, Rao HY. Gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced magnetic resonance imaging for evaluating fibrosis regression in chronic hepatitis C patients after direct-acting antiviral. World J Gastroenterol 2022; 28(20): 2214-2226 [DOI: 10.3748/wjg.v28.i20.2214] [Reference Citation Analysis]
4 Wu X, Roberto JB, Knupp A, Greninger AL, Truong CD, Hollingshead N, Kenerson HL, Tuefferd M, Chen A, Koelle DM, Horton H, Jerome KR, Polyak SJ, Yeung RS, Crispe IN. Response of Human Liver Tissue to Innate Immune Stimuli. Front Immunol 2022;13:811551. [PMID: 35355993 DOI: 10.3389/fimmu.2022.811551] [Reference Citation Analysis]
5 Aydın NN, Köksal İ. An Evaluation of Chronic Hepatitis C Patients’ Responses to Direct-Acting Antivirals According to Transient Elastography and Serum Biomarkers. vhd 2022;28:18-24. [DOI: 10.4274/vhd.galenos.2022.2021-8-2] [Reference Citation Analysis]
6 Pérez-Is L, Collazos J, de la Fuente B, Morano L, Rivas-Carmenado M, Rodriguez M, Romero-Favela A, Fonseca-González GJ, Melón S, Valle-Garay E, Asensi V. 24-month decline of non-invasive liver fibrosis markers in HCV-mono and HCV/HIV coinfection after direct-acting antiviral therapy. Sci Rep 2022;12:3828. [PMID: 35264591 DOI: 10.1038/s41598-022-07548-y] [Reference Citation Analysis]
7 Alswat K, Al-Sohaibani F, Khathlan A, Bashmail A, Alanazi M, Kurdi A, Almakadma AH, Al-Hamoudi W. Hepatic fibrosis changes in patients with chronic hepatitis C infection who respond to direct-acting antivirals. Ann Saudi Med 2022;42:89-95. [PMID: 35380056 DOI: 10.5144/0256-4947.2022.89] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Rosato V, Ascione A, Nevola R, Fracanzani AL, Piai G, Messina V, Claar E, Coppola C, Fontanella L, Lombardi R, Staiano L, Valente G, Fascione MC, Giorgione C, Mazzocca A, Galiero R, Perillo P, Marrone A, Sasso FC, Adinolfi LE, Rinaldi L. Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: A multicentre prospective study. J Viral Hepat 2022;29:26-34. [PMID: 34582610 DOI: 10.1111/jvh.13617] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Melendez-Mena D, Mendoza-Torres MA, Sedeño-Monge V, García Y García VH, Rivera-García E, Sánchez-Reza L, Baxin Domínguez MDC, Guzmán-Flores B, Martinez-Laguna Y, Coronel Espinoza JM, Galindo-Santiago I, Flores-Alonso JC, Vallejo-Ruiz V, Cortes-Hernandez P, Reyes-Leyva J, Sosa-Jurado F, Santos-López G. Effectiveness, tolerability and safety of Direct Acting Antivirals in Mexican individuals with Hepatitis C virus genotype-1 and previous pegylated interferon and ribavirin therapy. PeerJ 2021;9:e12051. [PMID: 34616602 DOI: 10.7717/peerj.12051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Kawaguchi T, Ide T, Amano K, Arinaga-Hino T, Kuwahara R, Sano T, Miki S, Ono N, Torimura T. Enhanced liver fibrosis score as a predictive marker for hepatocellular carcinoma development after hepatitis C virus eradication. Mol Clin Oncol 2021;15:215. [PMID: 34476099 DOI: 10.3892/mco.2021.2377] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Chen SH, Huang CL, Chiang IP, Chang TC, Wang HW, Hsu WF, Tsai TY, Peng CY. Liver fibrosis regression correlates with downregulation in liver angiogenesis in chronic hepatitis C through viral eradication. Eur J Gastroenterol Hepatol 2021;33:1209-17. [PMID: 32658008 DOI: 10.1097/MEG.0000000000001833] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
12 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, Clinical Practice Guideline Panel, Chair:, EASL Governing Board representative:, Panel members:. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 2021;75:659-89. [PMID: 34166721 DOI: 10.1016/j.jhep.2021.05.025] [Cited by in Crossref: 241] [Cited by in F6Publishing: 219] [Article Influence: 241.0] [Reference Citation Analysis]
13 Tsai YF, Liu YC, Yang CI, Chuang TM, Ke YL, Yeh TJ, Gau YC, Du JS, Wang HC, Cho SF, Hsu CM, Wu PF, Huang CI, Huang CF, Yu ML, Dai CY, Hsiao HH. Poor Prognosis of Diffuse Large B-Cell Lymphoma with Hepatitis C Infection. J Pers Med 2021;11:844. [PMID: 34575621 DOI: 10.3390/jpm11090844] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Kronfli N, Young J, Wang S, Cox J, Walmsley S, Hull M, Cooper C, Martel-Laferriere V, Wong A, Pick N, Klein MB; Canadian Coinfection Cohort Study Investigators. Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression? Clin Infect Dis 2021;73:468-77. [PMID: 32504083 DOI: 10.1093/cid/ciaa702] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
15 Barbosa WF, Andrade VG, Braz AMM, Winckler FC, Barbosa LR, Golim MA, Silveira LVA, Simões RP, Silva GF. Cirrhosis regression after SVR with indirect methods of fibrosis analysis: How far is it real? Clin Exp Med 2021. [PMID: 34347205 DOI: 10.1007/s10238-021-00749-1] [Reference Citation Analysis]
16 Peschel G, Grimm J, Buechler C, Gunckel M, Pollinger K, Aschenbrenner E, Kammerer S, Jung EM, Haimerl M, Werner J, Müller M, Weigand K. Liver stiffness assessed by shear-wave elastography declines in parallel with immunoregulatory proteins in patients with chronic HCV infection during DAA therapy. Clin Hemorheol Microcirc 2021. [PMID: 34120896 DOI: 10.3233/CH-211193] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
17 Estefan S, Brandão-Melo CE, Dos Santos Silva CM, Gomes DCK, Cardoso P, Costa MHS. Metabolic Evaluation in Patients With Hepatitis C Treated With Direct Antiviral Agents. Front Med (Lausanne) 2021;8:631600. [PMID: 34136497 DOI: 10.3389/fmed.2021.631600] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Saif-Al-Islam M, Abdelaal UM, Younis MA, Alghany Algahlan HA, Khalaf S. Effect of Direct-Acting Antiviral Therapy on Thrombocytopenic Patients with Hepatitis C Virus-Related Chronic Liver Disease. Gastroenterol Res Pract 2021;2021:8811203. [PMID: 34122539 DOI: 10.1155/2021/8811203] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Silva IPL, Batista AD, Lopes EP, Filgueira NA, Carvalho BT, Santos JC, Medeiros TB, Melo CRL, Lima MS, Lima K, Lacerda C, Lacerda HR. A real-life study on the impact of direct-acting antivirals in the treatment of chronic hepatitis C in liver transplant recipients at two university centers in Northeastern Brazil. Rev Inst Med Trop Sao Paulo 2021;63:e6. [PMID: 33533809 DOI: 10.1590/S1678-9946202163006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Su PY, Su WW, Wu LS, Hsu PK, Huang SP, Hsu YC. Reduction of Shear Wave Elastography but Not Shear Wave Dispersion After Successful Hepatitis C Treatment With Direct-Acting Antiviral Agents. J Ultrasound Med 2021;40:1919-26. [PMID: 33400288 DOI: 10.1002/jum.15576] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Debnath P, Nair S, Rathi P, Junare P, Jain S, Chandnani S, Singh A, Contractor Q. Serum biomarkers as an alternative to vibration controlled transient elastography in liver fibrosis staging in chronic hepatitis C. Acta Gastroenterol Belg 2021;84:43-50. [PMID: 33639692 DOI: 10.51821/84.1.776] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Fraquelli M, Fanetti I, Costantino A. Elastography After Treatment and During Follow-Up. Elastography of the Liver and Beyond 2021. [DOI: 10.1007/978-3-030-74132-7_9] [Reference Citation Analysis]
23 Wu X, Roberto JB, Knupp A, Greninger AL, Truong CD, Hollingshead N, Kenerson HL, Tuefferd M, Chen A, Horton H, Jerome KR, Polyak SJ, Yeung RS, Crispe IN. Response of human liver tissue to innate immune stimuli.. [DOI: 10.1101/2020.12.22.20248755] [Reference Citation Analysis]
24 Medeiros T, Saraiva GN, Moraes LA, Gomes AC, Lacerda GS, Leite PE, Esberard EB, Andrade TG, Xavier AR, Quírico-Santos T, Rosário NF, Silva AA. Liver fibrosis improvement in chronic hepatitis C after direct acting-antivirals is accompanied by reduced profibrogenic biomarkers-a role for MMP-9/TIMP-1. Dig Liver Dis 2020;52:1170-7. [PMID: 32522433 DOI: 10.1016/j.dld.2020.05.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
25 Ebid AIM, Ahmed OA, Agwa SH, Abdel-Motaleb SM, Hagag RS. Impact of IL28B gene polymorphism on efficacy and safety of direct acting antivirals in hepatitis C Egyptian patients. Int J Clin Pharm 2020;42:1207-16. [PMID: 32712884 DOI: 10.1007/s11096-020-01085-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]